Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.75 USD | -0.05% | +3.11% | -18.63% |
Jun. 04 | Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients | MT |
Jun. 04 | Bristol Myers: positive results in liver cancer | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.63% | 84.63B | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+17.02% | 246B | |
+9.26% | 213B | |
-4.21% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating